Want to see GB:SYNC full AI Analyst Report?
Top Page
Syncona Shs GBP
(LSE:SYNC)
Select Model
Select Model
Rating:60Neutral
Price Target:
112.00 p
▲(19.28% Upside)
Action:Reiterated
Date:06/19/26
The score is anchored by balance-sheet strength (debt-free, large equity base), but is held back by inconsistent profitability and a recent drop of free cash flow to zero. Technicals are supportive with the price above major moving averages and positive MACD, while valuation remains constrained by losses implied by the negative P/E.
Positive Factors
Zero debt balance sheet
A zero-debt balance sheet materially lowers financial risk and enhances resilience over multi-year development cycles. It gives Syncona durable funding flexibility to support portfolio companies through clinical milestones without near-term refinancing pressure, preserving optionality.
Negative Factors
Volatile profitability and revenue decline
Shifting from profit to consecutive loss years and recent revenue decline reduce visibility into NAV growth and long-term return generation. Persistent profitability volatility undermines predictability of distributable value and complicates multi-period planning for exits and reinvestment.
Read all positive and negative factors
Positive Factors
Negative Factors
Zero debt balance sheet
A zero-debt balance sheet materially lowers financial risk and enhances resilience over multi-year development cycles. It gives Syncona durable funding flexibility to support portfolio companies through clinical milestones without near-term refinancing pressure, preserving optionality.
Read all positive factors
Syncona Shs GBP (SYNC) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£650.77M
Dividend YieldN/A
Average Volume (3M)483.92K
Price to Earnings (P/E)―
Beta (1Y)0.38
Revenue Growth-40.88%
EPS Growth93.65%
CountryUK
Employees1,226
SectorFinancial
Sector Strength70
IndustryAsset Management
Share Statistics
EPS (TTM)-0.01
Shares Outstanding608,193,050
10 Day Avg. Volume510,558
30 Day Avg. Volume483,919
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)0.52
Price to Sales (P/S)9.39
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)£49.14M
Syncona Shs GBP Business Overview & Revenue Model
Company Description
Syncona Ltd. is a closed-end investment fund, which engages in delivering returns from investments in long and alternative investment funds across multiple asset classes and targets. Its portfolio includes commercial companies, late-stage clinical...
How the Company Makes Money
Syncona makes money primarily through investment returns from its life-sciences portfolio rather than through selling products or services itself. Its key economic driver is the change in value of its holdings (net asset value), which can increase...
Syncona Shs GBP Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
78
Positive
Cash Flow
53
Neutral
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 57.34M | -68.31M | 30.75M | -39.79M | 18.69M |
| Gross Profit | 43.36M | -68.31M | 14.10M | -51.91M | 3.68M |
| EBITDA | -8.80M | -143.16M | 8.14M | 0.00 | 11.15M |
| Net Income | -8.80M | -143.16M | 3.79M | -56.02M | 8.84M |
Balance Sheet | |||||
| Total Assets | 1.05B | 1.06B | 1.25B | 1.27B | 1.33B |
| Cash, Cash Equivalents and Short-Term Investments | 1.92M | 1.11M | 261.00K | 11.00K | 276.00K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 14.95M | 11.79M | 12.22M | 13.76M | 23.55M |
| Stockholders Equity | 1.04B | 1.05B | 1.24B | 1.25B | 1.31B |
Cash Flow | |||||
| Free Cash Flow | 0.00 | 43.91M | 20.47M | -265.00K | 262.00K |
| Operating Cash Flow | 23.33M | 43.91M | 20.47M | -265.00K | 262.00K |
| Investing Cash Flow | -15.75M | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | -6.78M | -43.06M | -20.22M | 0.00 | 0.00 |
Syncona Shs GBP Technical Analysis
Positive
93.90
Price Trends
100.36
Positive
95.97
Positive
97.04
Positive
Market Momentum
2.29
Positive
61.25
Neutral
25.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SYNC, the sentiment is Positive. The current price of 93.9 is below the 20-day moving average (MA) of 104.92, below the 50-day MA of 100.36, and below the 200-day MA of 97.04, indicating a bullish trend. The MACD of 2.29 indicates Positive momentum. The RSI at 61.25 is Neutral, neither overbought nor oversold. The STOCH value of 25.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:SYNC.
Syncona Shs GBP Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | £1.94B | 14.87 | 4.51% | 2.40% | 68.95% | 109.67% | |
72 Outperform | £1.39B | 11.90 | 14.60% | 9.91% | -21.74% | 58.92% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
65 Neutral | £1.02B | 8.66 | 8.51% | ― | -78.12% | 30945.45% | |
61 Neutral | £570.69M | 8.65 | 7.16% | ― | -35.12% | ― | |
60 Neutral | £650.77M | -74.31 | -9.02% | ― | -40.88% | 93.65% | |
52 Neutral | £113.91M | -13.30 | 1.79% | 3.29% | -2.25% | -353.75% |
* Financial Sector Average
GB:SYNC
Syncona Shs GBP
107.00
11.40
11.92%
GB:ASHM
Ashmore Group PLC
210.00
47.78
29.45%
GB:GROW
Molten Ventures
589.00
232.40
65.17%
GB:IPO
IP Group plc
64.60
6.00
10.24%
GB:MERC
Mercia Asset Management
27.00
-5.00
-15.63%
GB:CLDN
Caledonia Investments
380.50
27.76
7.87%
Syncona Shs GBP Corporate Events
Financial DisclosuresRegulatory Filings and ComplianceShareholder Meetings
Syncona Publishes 2026 Annual Report and Sets August AGM
Neutral
Jul 3, 2026
Syncona Ltd, the U.K.-listed life sciences investor, has released its Annual Report and Accounts for the year to 31 March 2026 alongside the formal notice of its 2026 Annual General Meeting. The documents have been filed with the Financial Conduct...
Other
Syncona Director Increases Stake with Share Purchase on London Stock Exchange
Positive
Jun 22, 2026
Syncona Limited reported that non-executive director John Patrick Roche purchased 16,063 ordinary shares of the company on 19 June 2026 at a price of £0.996 per share on the London Stock Exchange. The transaction, conducted in British pounds,...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresShareholder Meetings
Syncona Sets £250m Return Target as Portfolio Advances to Late-Stage Trials
Positive
Jun 18, 2026
Syncona reported largely stable full-year results, with net assets of £1.04 billion and modest gains in its life sciences portfolio driven by a valuation uplift at Beacon Therapeutics following an oversubscribed Series C financing. The group ...
Business Operations and StrategyExecutive/Board Changes
Syncona appoints veteran investment specialist Norman Crighton to board
Positive
Jun 17, 2026
Syncona Ltd has appointed veteran investment company specialist Norman Crighton as an independent non-executive director from 1 July 2026, adding more than three decades of experience in investment banking, fund management and board governance to ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.